about
Treatment with low-dose atorvastatin, losartan, and their combination increases expression of vasoactive-related genes in rat aortasArterial stiffness and cardiovascular therapyAssociations among different functional and structural arterial wall properties and their relations to traditional cardiovascular risk factors in healthy subjects: a cross-sectional study.Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical studyLong-term improvement of arterial wall characteristics in patients with diabetes mellitus type 1 using cyclic, intermittent treatment with a low-dose fluvastatin and valsartan combination.A low-dose atorvastatin and losartan combination directly improves aortic ring relaxation and diminishes ischaemic-reperfusion injury in isolated rat heartsReduction of age-associated arterial wall changes by low-dose valsartan.A low-dose combination of fluvastatin and valsartan: a new "drug" and a new approach for decreasing the arterial age.Improvement of arterial wall characteristics by the low-dose fluvastatin and valsartan combination in type 1 diabetes mellitus patients.Sub-therapeutic doses of fluvastatin and valsartan are more effective than therapeutic doses in providing beneficial cardiovascular pleiotropic effects in rats: A proof of concept study.Prevention of vascular complications in diabetes mellitus patients: focus on the arterial wall.A combination of low-dose fluvastatin and valsartan decreases inflammation and oxidative stress in apparently healthy middle-aged males.A new anti-ageing strategy focused on prevention of arterial ageing in the middle-aged population.The "Rise-Peak-Fall" Pattern of Time Dependency of the Cardiovascular Pleiotropic Effects of Treatment With Low-dose Atorvastatin, Losartan, and a Combination Thereof in Rats.The low-dose atorvastatin and valsartan combination effectively protects the arterial wall from atherogenic diet-induced impairment in the guinea pig.Low-Dose Fluvastatin and Valsartan Rejuvenate the Arterial Wall Through Telomerase Activity Increase in Middle-Aged Men.Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitusMolecular Mechanisms Responsible for Diastolic Dysfunction in Diabetes Mellitus PatientsExpression of Longevity Genes Induced by a Low-Dose Fluvastatin and Valsartan Combination with the Potential to Prevent/Treat "Aging-Related Disorders"Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males--a pilot studyThe effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trialVery low-dose fluvastatin-valsartan combination decreases parameters of inflammation and oxidative stress in patients with type 1 diabetes mellitusImprovement of arterial wall phenotype in subjects at moderate cardiovascular risk induced by very low-dose fluvastatin/valsartan combination: a pilot studyThe influence of May-Thurner syndrome on post-thrombotic syndrome in young women
P50
Q28577025-9F7B6516-F597-4639-9A28-842AB0817023Q34079790-A529A0B4-40D2-44C9-BAF6-4CE78E366DF6Q34245407-77D76E1F-4E54-4173-AD6B-D705B9AF031DQ34481839-30B591A5-4365-44CD-87CC-42985F555ABAQ35942738-B5B89D5D-D575-44D2-988E-94EB8C65F9F0Q36577081-6DB0ED0F-5F51-427A-B8EA-C735CB48C419Q39705754-0BCED394-CF04-4FEE-8739-4501C64BC697Q42180663-D34AFAA0-AD9E-4A80-A6EA-AA81717B1993Q46958950-35521EA1-FB14-4B44-BEE4-5484B02827CCQ47739583-CC1EA5AD-5A5C-451E-90BA-DC0316091E30Q50142930-5D3505BB-139A-45ED-BFAB-6CF2B50C7BF3Q51771095-5AB39719-B1A3-42F0-A488-DC7AAA197F79Q51818058-87834C08-7B4C-4060-A063-E0E10FF7D940Q53139968-E60764D7-0EF4-416A-BF83-8483E8CB35D0Q53828489-275DDFB0-013C-4BEF-AAB5-6AEB9444E6DEQ54256579-E0EC8C0C-C33D-4BFC-8981-3ACF33E7E209Q59795401-898B3D87-EC34-45F3-9D36-2A318876A5BEQ64111781-349158F3-89B6-42CB-919F-4E71D33714E6Q64249991-70B9F0B7-F326-4FFA-A2CE-D385F8B3DBFAQ83385937-2A853EB1-E949-4428-8D48-3C0CA7BCA1D6Q83562196-B324E33F-CA08-42BE-AE52-1B2DB65F932BQ87773582-B42453C3-D16C-4BF1-A426-9099B45F469EQ89306271-8244C9E4-EADF-4C0F-A7A7-5F9140D6AA2CQ92221543-0A34F32A-3B2F-4C95-8F91-D72C1CAE9CEA
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Miodrag Janić
@en
Miodrag Janić
@nl
type
label
Miodrag Janić
@en
Miodrag Janić
@nl
prefLabel
Miodrag Janić
@en
Miodrag Janić
@nl
P31
P496
0000-0001-7073-8922